Douglas Hixson, MD is a professor of medicine and pathology at Brown University and the director of the molecular carcinogenesis laboratory, division of medical oncology at Rhode Island Hospital. He received his research training at Purdue University and the University of Texas at Austin. He is internationally known for his research on hepatic stem cells and CEACAM1, an immunoglobulin-like tumor suppressor. The author of more than 80 research articles and book chapters, he is currently the principal investigator (PI) of three NIH RO1 cancer research grants. Dr. Hixson has served on multiple NIH review panels and was past chair of the NIH Chemical Pathology Study Section. He is on the editorial board of hepatology
One Hoppin Street • Providence, RI 02903
Phone: 401-444-2871 • email: ESmith6@lifespan.org
Douglas Hixson, MD is a professor of medicine and pathology at Brown University and the director of the molecular carcinogenesis laboratory, division of medical oncology at Rhode Island Hospital. He received his research training at Purdue University and the University of Texas at Austin. He is internationally known for his research on hepatic stem cells and CEACAM1, an immunoglobulin-like tumor suppressor. The author of more than 80 research articles and book chapters, he is currently the principal investigator (PI) of three NIH RO1 cancer research grants. Dr. Hixson has served on multiple NIH review panels and was past chair of the NIH Chemical Pathology Study Section. He is on the editorial board of hepatology